Primary Sclerosing Cholangitis

Interim analyses of two phase 2b studies of volixibat support its use as potential treatment for patients with primary biliary cholangitis and primary sclerosing cholangitis, according to a press release from Mirum Pharmaceuticals.

Researchers identified bile duct dysplasia or cancer in most explanted livers with an indication of biliary dysplasia, although as many as 41% had no signs of neoplasia, according to a study of patients with primary sclerosing cholangitis.

WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.

In this exclusive Healio interview, Gideon Hirschfield, PhD, MB Bchir, the Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto, discusses the latest insights into the gut microbiome’s role as a key player in disease development and progression.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial presented at The Liver Meeting, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo.

The FDA has granted fast track designation to Chemomab Therapeutics’ anti-CCL24 monoclonal antibody, CM-101, for the treatment of adults with primary sclerosing cholangitis, according to a manufacturer release.

SAN DIEGO — Statin therapy decreased the risk for developing acute cholangitis among patients with primary sclerosing cholangitis, according to research presented at Digestive Disease Week 2022.

Ursodeoxycholic acid treatment correlated with reduced mortality, need for liver transplantation and biliary tract cancer in patients with primary sclerosing cholangitis, according to a presenter at The Liver Meeting Digital Experience.

Healio Gastroenterology presents the following reports on the most recent research on inflammatory bowel disease.